Company Overview

Becton, Dickinson and Company (BD), traded on the NYSE under the ticker BDX, is a global medical technology company focused on the development, manufacture, and sale of medical devices, laboratory equipment, diagnostic products, and biosciences tools. The company operates primarily in the healthcare and life sciences industries, serving hospitals, laboratories, physicians, researchers, pharmaceutical companies, and public health agencies. BD’s major revenue drivers include medication delivery systems, diagnostic testing platforms, biosciences instruments, interventional devices, and surgical products. The company is widely recognized for its scale in consumable medical products such as syringes, needles, catheters, infusion systems, and specimen collection technologies.

Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, BD began as an importer of medical supplies and evolved into one of the world’s largest medical technology manufacturers through internal product development and acquisitions. The company expanded significantly through acquisitions including CareFusion in 2015 and C. R. Bard in 2017, which broadened its presence in medication management, infection prevention, vascular care, urology, oncology, and surgical technologies. BD’s strategic positioning is supported by its extensive installed base in healthcare systems, recurring consumables revenue model, global manufacturing footprint, and long-standing relationships with healthcare providers and laboratory networks.

Business Operations

BD organizes its operations into three primary business segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on medication delivery solutions, medication management systems, advanced patient monitoring technologies, pharmaceutical systems, and diabetes care products. BD Life Sciences provides diagnostic systems, specimen management, molecular diagnostics, flow cytometry instruments, and research tools used in clinical and academic laboratories. BD Interventional develops products for peripheral vascular disease, oncology, surgery, infection prevention, hernia repair, urology, and critical care procedures. Revenue is generated through both capital equipment sales and recurring consumable product demand, with consumables representing a substantial portion of recurring revenue.

The company operates manufacturing, research, and distribution facilities across North America, Europe, Asia-Pacific, Latin America, and the Middle East. BD controls a broad portfolio of proprietary technologies related to drug delivery, molecular testing, biosciences instrumentation, robotics-assisted medication management, and minimally invasive intervention systems. Major subsidiaries include CareFusion, C. R. Bard, and multiple regional operating entities integrated into BD’s global platform. BD also maintains partnerships with healthcare providers, pharmaceutical firms, and public health organizations to support diagnostics development, medication safety initiatives, and infectious disease surveillance programs.

Strategic Position & Investments

BD’s strategic direction has centered on expanding higher-growth medical technology categories, improving operational efficiency, and increasing recurring revenue streams tied to hospital and laboratory workflows. The company has invested heavily in automation, connected care systems, advanced diagnostics, and minimally invasive therapeutic technologies. Its acquisition of CareFusion strengthened medication management and infusion capabilities, while the acquisition of C. R. Bard significantly expanded BD’s interventional medicine portfolio, particularly in vascular, oncology, and surgical markets. BD has also continued investing in research and development initiatives targeting robotics-enabled medication preparation, next-generation flow cytometry, molecular diagnostics, and smart connected infusion technologies.

The company has maintained a strong presence in emerging healthcare trends including infection prevention, biosurveillance, precision diagnostics, and outpatient procedural care. BD has also invested in manufacturing capacity and supply-chain resilience following heightened global demand for diagnostic testing and injection devices during and after the COVID-19 pandemic. Public filings and investor disclosures indicate that the company continues to prioritize margin expansion, innovation-led growth, and selective portfolio optimization. BD has periodically divested non-core assets while increasing focus on integrated healthcare technology ecosystems that combine devices, software, analytics, and consumables.

Geographic Footprint

BD is headquartered in Franklin Lakes, New Jersey, and operates in more than 190 countries. The company maintains a substantial commercial and manufacturing presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The United States remains its largest market, though international operations contribute a significant share of total revenue through hospital systems, diagnostic laboratories, and government healthcare agencies worldwide.

The company’s manufacturing and supply-chain infrastructure includes facilities in the United States, Mexico, Puerto Rico, Ireland, Spain, France, Germany, China, India, and Singapore, among other locations. BD has expanded its influence in emerging markets through regional investments, local production capabilities, and distribution partnerships aimed at improving access to diagnostics and medical technologies. Its global reach is reinforced by broad regulatory approvals, established hospital procurement relationships, and long-term participation in public health and immunization programs.

Leadership & Governance

BD operates under a governance structure led by a board of directors and executive leadership team focused on innovation, operational execution, and long-term healthcare system integration. The company emphasizes patient safety, technological innovation, and global healthcare access as central components of its corporate strategy. Public disclosures and executive communications indicate a strategic focus on advancing smart connected care, improving clinical outcomes, and strengthening recurring revenue through integrated medical technologies.

Key executives include:

• Thomas E. Polen – Chairman, Chief Executive Officer, and President
• Christopher DelOrefice – Executive Vice President and Chief Financial Officer
• David Shan – Executive Vice President and Chief Integrated Supply Chain Officer
• Tami Reller – Executive Vice President, Chief Legal Officer, and Corporate Secretary
• Brooke Story – Executive Vice President and President of BD Integrated Diagnostic Solutions
• Michael Garrison – Executive Vice President and President of BD Medical
• Sanjay Banerjee – Executive Vice President and President of BD Interventional

The company’s governance and operational disclosures are primarily documented through SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, earnings presentations, and investor communications. Information presented above aligns with publicly available company filings and major financial reporting sources.